Agent for prevention, treatment or amelioration of psoriasis

Enterococcus faecalis strain NF-1011 and its components provide a safe and effective oral treatment for psoriasis by reducing skin inflammation and abnormal cell proliferation, addressing the limitations of current therapies.

JP2024157617APending Publication Date: 2024-11-08THE RITSUMEIKAN TRUST +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2023072058
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current treatments for psoriasis, such as corticosteroids, vitamin D derivatives, immunosuppressants, and biologics, are not curative and often have significant side effects, necessitating a safer and more effective therapeutic agent.

Method used

An agent containing lactic acid bacteria from the genus Enterococcus, particularly Enterococcus faecalis strain NF-1011, or its bacterial cell components, is administered orally to suppress psoriasis symptoms.

Benefits of technology

The lactic acid bacteria and their components effectively treat, prevent, and improve psoriasis symptoms by reducing skin inflammation and abnormal cell proliferation, demonstrating safety and efficacy in psoriasis model mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024157617000001
    Figure 2024157617000001
  • Figure 2024157617000002
    Figure 2024157617000002
  • Figure 2024157617000003
    Figure 2024157617000003
Patent Text Reader

Abstract

To provide an agent for prevention, treatment or amelioration of psoriasis.SOLUTION: An agent for prevention, treatment or amelioration of psoriasis contains at least one selected from the group consisting of cells and cellular components of lactic acid bacteria from the Enterococcus genus.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an agent for preventing, treating or ameliorating psoriasis. [Background technology]

[0002] Psoriasis is a chronic skin disease characterized by skin inflammation and abnormal proliferation of keratinocytes. The cause of psoriasis has not yet been fully elucidated, and it is believed to develop due to genetic factors combined with various external factors (infection, stress, drugs, etc.), and the main cause is thought to be deviation from the normal proliferation and differentiation mechanisms of skin cells. In recent years, it has been shown that abnormalities in immune function are involved. Psoriasis is broadly classified into five types, namely psoriasis vulgaris, psoriatic arthropathy (psoriatic arthritis), guttate psoriasis, erythrodermic psoriasis, and pustular psoriasis. Psoriasis is a lymphocyte abnormality, and symptoms include erythema, scales, infiltration, and thickening.

[0003] Corticosteroids, vitamin D3 derivatives, immunosuppressants (cyclosporine, etc.), vitamin A derivatives (retinoids), biological agents (e.g., anti-TNF-α antibodies), photochemotherapy (PUVA), etc. are used to treat psoriasis, but satisfactory therapeutic effects have not always been achieved. Furthermore, there are various problems in terms of side effects, and there is room for improvement. Currently, anti-IL-17 antibody therapy has been established and is highly effective for severe psoriasis pathology. However, these treatment approaches are limited and not curative. Since symptoms recur when treatment is discontinued, biological agents must be administered throughout the patient's life. Therefore, there is a need for a more effective and safer type of psoriasis treatment that is different from existing treatments.

[0004] Lactic acid bacteria have been known to affect the intestinal flora, and their effects have been reported to include various other functions in addition to intestinal regulation. Lactic acid bacteria belonging to the genus Enterococcus are also known to have a variety of effects on the body.

[0005] For example, Enterococcus faecalis NF-1011 strain has been reported to have blood pressure elevation inhibitory effects and cardiac hypertrophy prevention effects (Patent Document 1), immunostimulatory effects (Patent Document 2), interferon production enhancement effects (Patent Document 3), infection prevention effects (Patent Document 4), anticancer enhancement effects (Patent Document 5), toxicity reduction effects of anticancer drugs (Patent Document 6), and cancer metastasis inhibition effects (Patent Document 7). [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Publication No. 5-201871 [Patent Document 2] Japanese Patent Application Publication No. 8-99887 [Patent Document 3] Japanese Patent Application Publication No. 8-259450 [Patent Document 4] Japanese Patent Application Publication No. 8-283166 [Patent Document 5] Japanese Patent Application Publication No. 8-295631 [Patent Document 6] Japanese Patent Application Publication No. 9-48733 [Patent Document 7] JP 2019-131475 A Summary of the Invention [Problem to be solved by the invention]

[0007] An object of the present invention is to provide an agent for preventing, treating or ameliorating psoriasis. [Means for solving the problem]

[0008] As a result of extensive research aimed at achieving the above-mentioned objective, the inventors have discovered that Enterococcus faecalis NF-1011 strain cells and its cell components can suppress the symptoms of psoriasis when orally administered to psoriasis model mice.

[0009] The present invention has been completed based on these findings and through further investigation, and provides the following agent for preventing, treating or ameliorating psoriasis.

[0010] Item 1. An agent for preventing, treating or ameliorating psoriasis, comprising at least one species selected from the group consisting of lactic acid bacteria belonging to the genus Enterococcus and components thereof. Item 2. The agent according to Item 1, wherein the lactic acid bacterium belonging to the genus Enterococcus is Enterococcus faecalis. Item 3. The agent according to Item 1, wherein the lactic acid bacterium belonging to the genus Enterococcus is Enterococcus faecalis NF-1011 strain (FERM BP-10902). Item 4. The agent according to any one of Items 1 to 3, wherein the bacterial cells are killed bacterial cells. Item 5. The agent according to any one of Items 1 to 4, wherein the bacterial component of the lactic acid bacteria is a lytic enzyme or a heat-treated product of the lactic acid bacteria. Item 6. The agent according to any one of Items 1 to 5, which is in an oral dosage form. Item 7. The agent according to any one of Items 1 to 5, which is a food composition. Item 8. The agent according to any one of Items 1 to 5, which is a food additive. Item 9. The agent according to any one of Items 1 to 7, which is a medicine. Effect of the Invention

[0011] Since the cells of lactic acid bacteria belonging to the genus Enterococcus and their cell components have remarkably excellent therapeutic, preventive and ameliorative effects on psoriasis, they are useful as active ingredients of agents for preventing, treating or ameliorating psoriasis. [Brief description of the drawings]

[0012] [Figure 1] This is a photograph of the back of a mouse that was treated with imiquimod and administered FK-23. [Diagram 2]Photographs of paraffin sections of skin tissue from mice treated with imiquimod and administered FK-23, and a graph showing epidermal thickness. Data are mean ± standard error, **: P<0.01 vs CRL, ††: P<0.01 vs IMQ, Tukey's post-hoc test. [Diagram 3] Graph showing clinical scores (PASI) of mice treated with imiquimod and administered FK-23. Data are mean ± standard error, ***: P<0.005 vs CRL, †††: P<0.005 vs IMQ, Tukey's post-hoc test. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Hereinafter, an embodiment of the present invention will be described.

[0014] As used herein, "psoriasis" refers to a chronic, recurrent inflammatory parakeratosis characterized by abnormal proliferation and differentiation of epidermal cells and infiltration of inflammatory cells, and the typical symptom is a well-defined red papule or plaque covered with silvery scales. Psoriasis is thought to develop due to a combination of genetic predisposition and various environmental factors.

[0015] The agent for preventing, treating or ameliorating psoriasis of the present invention is characterized by containing at least one species selected from the group consisting of lactic acid bacteria belonging to the genus Enterococcus and bacterial components thereof.

[0016] Lactic acid bacteria belonging to the genus Enterococcus are not particularly limited, and examples thereof include Enterococcus faecalis, Enterococcus faecium, Enterococcus avium, Enterococcus casseliflavus, Enterococcus gallinarum, and Enterococcus flavescens. Among these, Enterococcus faecalis and Enterococcus faecium are preferred, and Enterococcus faecalis is more preferred. Among Enterococcus faecalis, Enterococcus faecalis NF-1011 strain, which is a strain isolated from feces of healthy individuals, is preferred. Enterococcus faecalis NF-1011 strain was deposited on October 8, 1991 at the National Institute of Advanced Industrial Science and Technology (Chuo 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan (Postal Code 305-8566)) under the accession number FERM P-12564. This strain has now been transferred to an international depository, and its accession number is FERM BP-10902. The National Institute of Advanced Industrial Science and Technology (AIST) Patent Organism Depositary was integrated with the National Institute of Technology and Evaluation (NITE) Patent Microorganism Depositary in April 2012, and the microbial depository business is currently being taken over by the National Institute of Technology and Evaluation Biotechnology Center Patent Organism Depositary (NITE-IPOD) (Room 120, 2-5-8 Kazusa Kamatari, Kisarazu, Chiba, Japan 292-0818).

[0017] The bacterial cells of the lactic acid bacteria belonging to the genus Enterococcus are not particularly limited as long as they are the entire constituents of the lactic acid bacteria belonging to the genus Enterococcus, and may be live or killed. The bacterial cells may be dried, such as freeze-dried. Live bacterial cells of the lactic acid bacteria belonging to the genus Enterococcus can be ordered from domestic distribution organizations such as ATCC, IFO, JCM, and international distribution organizations, or can be isolated from living organisms.

[0018] In addition, since they can be easily obtained in large quantities by culturing, using live cells obtained by culturing is economical because the production cost is low. Live cells of lactic acid bacteria belonging to the genus Enterococcus can also be grown by culturing according to a known method. For example, the lactic acid bacteria are inoculated into an appropriate amount of sterilized Rogoza liquid medium, and aerobically cultured at 35 to 37°C for 10 to 16 hours under static conditions to obtain a preculture solution, which is added to a large volume of sterilized Rogoza liquid medium and similarly cultured under static conditions to obtain a large amount of live cells. When live cells are used, for example, the culture solution itself may be used, or the solid content of the culture solution (for example, a precipitate obtained by precipitating live cells from the culture solution by centrifugation or the like, and then washing with saline or the like as necessary, a precipitate obtained by washing with saline or the like) may be used, or a suspension of the solid content (for example, a suspension obtained by suspending in an isotonic solution such as saline) may be used.

[0019] The killed cells of lactic acid bacteria belonging to the genus Enterococcus are not particularly limited, but may be, for example, heat-treated live cells. The temperature of the heat treatment is not particularly limited as long as it is 100°C or higher, but is preferably a temperature at which autoclaving is possible (e.g., 110 to 125°C). The heat treatment time is, for example, 1 minute or more, preferably 5 to 20 minutes, and more preferably about 5 to 15 minutes.

[0020] Lactic acid bacteria Enterococcus faecalis strain NF-1011 is commercially available from Nichi Nichi Pharmaceutical Co., Ltd. under the trade name FK-23 (trademark), for example.

[0021] In the present invention, the term "cellular components of lactic acid bacteria" refers to components that are released outside the cells when the cell walls of lactic acid bacteria are destroyed.

[0022] The bacterial component of lactic acid bacteria is not particularly limited, but may be, for example, a product of cell wall destruction treatment of live bacterial cells. This cell wall destruction may be the whole or a part of the cell wall of the live bacterial cells. Examples of the cell wall destruction treatment method include heat treatment, treatment by physical force, treatment by lytic enzyme, etc., or a combination of these treatments. Among these, a method including a treatment by a lytic enzyme is preferable, a method including (a) a treatment by a lytic enzyme and at least one treatment (preferably heat treatment) selected from the group consisting of (b) a heat treatment and a treatment by physical force is more preferable, and a method including (a) a treatment by a lytic enzyme followed by at least one treatment (preferably heat treatment) selected from the group consisting of (b) a heat treatment and a treatment by physical force is even more preferable.

[0023] The temperature of the heat treatment is not particularly limited as long as it is 100°C or higher, but is preferably a temperature at which autoclaving is possible (for example, 110 to 125°C). The heat treatment time is not particularly limited as long as it is possible to destroy part or all of the cell walls, and can be appropriately set depending on the heat treatment temperature. The heat treatment time is, for example, 1 minute or more, preferably 5 to 20 minutes, and more preferably about 5 to 15 minutes.

[0024] The method of treatment with a physical force is not particularly limited as long as it can destroy part or all of the cell walls, and examples thereof include ultrasonic treatment and French press.

[0025] The enzyme used in the treatment with the lytic enzyme is not particularly limited as long as it can destroy part or all of the cell wall, and a wide variety of enzymes commonly used to lyse bacteria can be used. Examples of the lytic enzyme include lysozyme, actinase, zymolyase, chitalase, mutanocillin, achromopeptidase, and the like. Among these, lysozyme is preferred. The lytic enzyme may be used alone or in combination of two or more kinds.

[0026] The conditions for treatment with a lytic enzyme can be appropriately set depending on the type of lytic enzyme, the amount of the target to be lysed (viable cells), etc. For example, the lytic enzyme may be added to the viable cell suspension to a final concentration of 0.01 to 1 mg / mL, and the treatment may be performed at 30 to 40° C. for 1 to 10 hours.

[0027] The bacterial component of the lactic acid bacteria is not particularly limited as long as it is a component constituting the bacterial body of the lactic acid bacteria. The bacterial component is preferably a water-soluble component. The water-soluble component can be obtained, for example, by removing solids from a product obtained by disrupting the cell wall of the lactic acid bacteria by centrifugation or the like.

[0028] A bacterial component of the lactic acid bacteria Enterococcus faecalis strain NF-1011 is commercially available, for example, from Nichi Nichi Pharmaceutical Co., Ltd. under the name LFK (registered trademark).

[0029] The lactic acid bacteria belonging to the genus Enterococcus can be used alone or in combination of two or more kinds.

[0030] The agent of the present invention can be used in various fields, for example, as a medicine, a food composition (including, for example, health foods, nutritional supplements (balanced nutritional foods, supplements, etc.), nutritional functional foods, foods for specified health uses, foods with functional claims, etc.), food additives, etc.

[0031] The formulation of the agent of the present invention is not particularly limited, and can be in a formulation form that is commonly used in each field of use according to the field of use of the agent of the present invention. By concentrating the essential components as necessary, even a large amount of bacteria or its bacterial components can be prepared into a dosage form that can be administered. Examples of the formulation form include formulation forms suitable for oral intake (oral formulation forms) such as tablets (including oral disintegrating tablets, chewable tablets, effervescent tablets, lozenges, jelly-like drops, etc.), pills, granules, fine granules, powders, hard capsules, soft capsules, dry syrups, liquids (including drinks, suspensions, syrups, etc.), and jellies, and formulation forms suitable for parenteral intake (parenteral formulation forms) such as injections, patches, lotions, and creams, and preferably oral formulation forms. In particular, examples of food compositions include liquid, gel, or solid foods, such as balanced nutritional foods such as gums, confectioneries such as tablet candies, and beverages such as nutritional drinks, powders, capsules, and tablets.

[0032] In addition to the essential ingredients, the agent of the present invention may be appropriately blended with other ingredients depending on the field of use, the formulation form, etc. The ingredients that can be blended are not particularly limited, and examples thereof include water, amino acids, alcohols, polyhydric alcohols, polymeric compounds such as sugars, gums, and polysaccharides, surfactants, preservatives, antibacterial agents, and bactericides, pH adjusters, chelating agents, antioxidants, enzyme components, binders, disintegrants, lubricants, fluidizing agents, and refreshing agents, as well as minerals, cell activators, nutrient tonics, excipients, thickeners, stabilizers, preservatives, isotonicity agents, dispersants, adsorbents, disintegration aids, wetting agents or wetting regulators, moisture-proofing agents, colorants, flavorings or fragrances, fragrances, reducing agents, solubilizers, dissolution aids, foaming agents, thickening agents or thickening agents, solvents, bases, emulsifiers, plasticizers, buffers, and glossing agents.

[0033] The content of the essential components in the agent of the present invention is not particularly limited since it can be appropriately selected depending on the form of use. The essential components may be blended in an effective amount in the agent of the present invention, and the essential components may be blended in a ratio of usually 0.001-60%, more preferably 0.01-40%, particularly preferably 0.1-30% by dry mass relative to the mass of the agent of the present invention.

[0034] The application amount (e.g., administration, ingestion, inoculation, etc.) of the agent of the present invention can be appropriately increased or decreased depending on the symptoms, age and body weight of the patient, formulation form, etc. The daily dose of the agent can be generally 0.001 to 0.5 g / kg body weight, preferably 0.002 to 0.1 g / kg body weight, calculated as the dry mass of the essential ingredient for an adult, and can be administered once a day or in divided doses.

[0035] The agent of the present invention is applicable to mammals (humans, monkeys, dogs, cats, horses, cows, mice, rats, guinea pigs, pigs, rabbits, sheep, etc.), particularly humans.

[0036] As shown in the Examples below, the present inventors have found that oral administration of lactic acid bacteria belonging to the genus Enterococcus to psoriasis model mice can suppress psoriasis symptoms (skin symptoms, epidermal thickening). Based on this action, it has been shown that the bacteria and bacterial components of lactic acid bacteria belonging to the genus Enterococcus can be expected to have therapeutic, preventive and ameliorative effects on psoriasis. As a result, the bacteria and bacterial components of lactic acid bacteria belonging to the genus Enterococcus are useful as active ingredients for preventing, treating or ameliorating psoriasis.

[0037] The active ingredients, lactic acid bacteria belonging to the genus Enterococcus and their bacterial components, are substances that have traditionally been ingested as food and are therefore highly safe.

[0038] It should be noted that in this specification, the term "comprising" includes "consisting essentially of" and "consisting of."

[0039] Furthermore, the various characteristics (properties, structures, functions, etc.) described in each embodiment of the present invention above may be combined in any way to specify the subject matter included in the present invention. In other words, the present invention includes all subject matter consisting of all combinations of the combinable characteristics described in this specification. EXAMPLES

[0040] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.

[0041] Method for preparing bacterial samples 1.FK-23 Enterococcus faecalis NF-1011 strain was cultured in liquid medium at 37℃ for 18 hours. The bacteria were harvested by centrifugation and washed with distilled water, then heat-treated at 110℃ for 10 minutes, and then dried by spray drying. The resulting dried killed bacteria was used as the bacterial sample (FK-23) in the following experiments.

[0042] Test Example <Experimental Method> Mouse and Instructions Seven-week-old male mice were obtained from Japan SLC Co., Ltd. and were housed in a semi-barrier animal room (12:12 light / dark cycle, free access (water or 2% FK-23)) for one week. The mice were divided into three groups: control (CRL), imiquimod application (IMQ), and IMQ application + oral administration of 2% FK-23 (IMQ+FK-23). ​​C57BL / 6N mice were shaved and 24 hours later, 62.5 mg / cm 2 Imiquimod (IMQ) cream (5%) (Mochida Pharmaceutical Co., Ltd.) was applied to the backs of 8-week-old mice for 6 consecutive days (days 0–6). Disease severity was assessed using a modified Psoriasis Area and Severity Index (PASI) scoring system, a composite score of erythema, scaling, and skin thickening, each independently, for a total possible score of 12 points (modified PASI), ranging from no visible phenotype (0) to severe (5). Dorsal skin of mice was harvested 6 days after IMQ application. Samples were fixed in 10% formalin and embedded in paraffin for immunohistochemical evaluation. All animal protocols were approved by the Ritsumeikan University Animal Care and Use Committee (BKC2021-026).

[0043] ·Histological analysis Tissues were fixed in 10% (w / v) paraformaldehyde and embedded in paraffin blocks as previously reported. Blocks were sectioned using a microtome (Leica Biosystems). Sections (5 μm thick) were stained with hematoxylin and eosin (H&E) and images were acquired using a microscope (BX51 / DP74) and cellSens software (Olympus Corporation), and epidermal thickness was measured.

[0044] ·Statistical analysis Significance was tested using one-way analysis of variance (ANOVA), and P values ​​less than 0.05 were considered significant.

[0045] <Result> The probiotic FK-23 has no proven efficacy against psoriasis. Therefore, we investigated the effect of FK-23 in a mouse model of imiquimod-induced psoriasis. The results are shown in Figures 1-3.

[0046] Figure 1 shows the results of the observation of skin symptoms. As can be seen from Figure 1, the effect of imiquimod was suppressed in the imiquimod + FK-23 group. Figure 2 shows a photograph of a paraffin section of mouse skin tissue. The imiquimod group had a thicker epidermis than the non-imiquimod group, whereas the imiquimod + FK-23 group had suppressed acanthosis compared to the imiquimod group. This indicates that FK-23 has a protective effect against acanthosis.

[0047] Furthermore, in FIG. 3, the imiquimod application group had a significantly higher PASI than the imiquimod non-application group, and the effect of imiquimod was significantly suppressed in the imiquimod application + FK-23 group.

Claims

1. An agent for preventing, treating or improving psoriasis, comprising at least one species selected from the group consisting of lactic acid bacteria belonging to the genus Enterococcus and components thereof.

2. The agent according to claim 1, wherein the lactic acid bacterium belonging to the genus Enterococcus is Enterococcus faecalis.

3. The agent according to claim 1, wherein the lactic acid bacterium belonging to the genus Enterococcus is Enterococcus faecalis NF-1011 strain (FERM BP-10902).

4. The agent according to claim 1 or 2, wherein the bacterial cells are killed bacterial cells.

5. The agent according to claim 1 or 2, wherein the bacterial components of the lactic acid bacteria are a lytic enzyme and a heat-treated product of the lactic acid bacteria.

6. The agent according to claim 1 or 2, which is in an oral dosage form.

7. The agent according to claim 1 or 2, which is a food composition.

8. The agent according to claim 1 or 2, which is a food additive.

9. The agent according to claim 1 or 2, which is a medicine.

Citation Information

Patent Citations

  • Agent for inhibiting rise of blood pressure and for preventing cardiomegaly

    JP1993201871A

  • Immunopotentiator

    JP1996099887A

  • Enhancer for production of interferon

    JP1996259450A

  • Prophylactic agent

    JP1996283166A

  • Anticancer potentiator

    JP1996295631A